ATE307136T1 - Agonisten für den adenosin a3 rezeptor - Google Patents

Agonisten für den adenosin a3 rezeptor

Info

Publication number
ATE307136T1
ATE307136T1 AT02763415T AT02763415T ATE307136T1 AT E307136 T1 ATE307136 T1 AT E307136T1 AT 02763415 T AT02763415 T AT 02763415T AT 02763415 T AT02763415 T AT 02763415T AT E307136 T1 ATE307136 T1 AT E307136T1
Authority
AT
Austria
Prior art keywords
adenosine
agonists
receptor
neutropennia
leukopenia
Prior art date
Application number
AT02763415T
Other languages
English (en)
Inventor
Elfatih Elzein
Venkata Palle
Vaibhav Varkhedkar
Jeff Zablocki
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Application granted granted Critical
Publication of ATE307136T1 publication Critical patent/ATE307136T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT02763415T 2001-08-08 2002-08-06 Agonisten für den adenosin a3 rezeptor ATE307136T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31106901P 2001-08-08 2001-08-08
PCT/US2002/024696 WO2003014137A1 (en) 2001-08-08 2002-08-06 Adenosine a3 receptor agonists

Publications (1)

Publication Number Publication Date
ATE307136T1 true ATE307136T1 (de) 2005-11-15

Family

ID=23205248

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02763415T ATE307136T1 (de) 2001-08-08 2002-08-06 Agonisten für den adenosin a3 rezeptor

Country Status (20)

Country Link
US (1) US20030078232A1 (de)
EP (1) EP1414837B1 (de)
JP (1) JP4357960B2 (de)
KR (1) KR100923888B1 (de)
CN (1) CN1244589C (de)
AT (1) ATE307136T1 (de)
AU (1) AU2002327426C1 (de)
CA (1) CA2456744A1 (de)
DE (1) DE60206775T2 (de)
DK (1) DK1414837T3 (de)
ES (1) ES2247371T3 (de)
HU (1) HUP0401437A3 (de)
IL (2) IL160231A0 (de)
MX (1) MXPA04001185A (de)
NO (1) NO327997B1 (de)
NZ (1) NZ530976A (de)
PL (1) PL368205A1 (de)
RU (1) RU2298557C2 (de)
WO (1) WO2003014137A1 (de)
ZA (1) ZA200401000B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
WO2002088107A1 (en) * 2001-04-26 2002-11-07 Eisai Co., Ltd. Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof
SG176313A1 (en) * 2001-10-01 2011-12-29 Univ Virginia Patent Found 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
WO2004022573A2 (en) * 2002-09-09 2004-03-18 Cv Therapeutics, Inc. Adenosine a3 receptor agonists
WO2004086034A2 (en) * 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a3(adora3)
EP1651612B9 (de) 2003-07-22 2012-09-05 Astex Therapeutics Limited 3,4-disubstituierte 1h-pyrazol-verbindungen und deren verwendung als cyclin-abhängige kinase (cdk) und glycogen synthase kinase-3 (gsk-3) modulatoren
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
WO2006028618A1 (en) 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
WO2006023272A1 (en) 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
CN101083998A (zh) * 2004-11-22 2007-12-05 王者制药研究发展有限公司 用腺苷a3受体激动剂强化治疗hif－1介导的病症
WO2006077428A1 (en) 2005-01-21 2006-07-27 Astex Therapeutics Limited Pharmaceutical compounds
GB0505219D0 (en) * 2005-03-14 2005-04-20 Novartis Ag Organic compounds
US7381714B2 (en) * 2005-05-19 2008-06-03 Cv Therapeutics, Inc. A1 adenosine receptor agonists
WO2006125211A1 (en) * 2005-05-19 2006-11-23 Cv Therapeutics, Inc. A1 adenosine receptor agonists
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
CA2625783A1 (en) * 2005-10-13 2007-04-26 Elfatih Elzein A1 adenosine receptor agonists
WO2007120972A2 (en) 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
US7589076B2 (en) * 2006-05-18 2009-09-15 Pgx Health, Llc Substituted aryl piperidinylalkynyladenosines as A2AR agonists
US8188063B2 (en) 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
DE102007012645A1 (de) 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
EP2142545A1 (de) 2007-03-28 2010-01-13 NeuroSearch A/S Purinylderivate und ihre verwendung als kaliumkanalmodulatoren
JP2010522720A (ja) * 2007-03-28 2010-07-08 ノイロサーチ アクティーゼルスカブ プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用
US20090088403A1 (en) * 2007-05-07 2009-04-02 Randy Blakely A3 adenosine receptors as targets for the modulation of central serotonergic signaling
US20090099212A1 (en) * 2007-10-16 2009-04-16 Jeff Zablocki A3 adenosine receptor antagonists
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
RU2451010C1 (ru) * 2011-01-11 2012-05-20 Закрытое Акционерное Общество "Ива Фарм" Палладиево-медные катализаторы гомогенного селективного окисления тиольных групп, комбинация и композиция на их основе и способ терапевтического воздействия
CN104411703A (zh) 2012-06-26 2015-03-11 萨尼奥纳有限责任公司 苯基三唑衍生物及其调节gabaa受体复合体的用途
WO2014138485A1 (en) * 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof
US11014954B2 (en) 2017-05-19 2021-05-25 Alltech, Inc. Pharmaceutical agents, compositions, and methods relating thereto
US20220332750A1 (en) * 2019-06-21 2022-10-20 Academy Of Military Medical Sciences Adenosine compound, its pharmaceutically acceptable salt or its stereoisomer and use thereof
EP4273153A4 (de) * 2020-12-29 2024-05-08 Zhejiang Vimgreen Pharmaceuticals Ltd Adenosin-a3-rezeptoragonisten, herstellungsverfahren und verwendungen davon

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6180615B1 (en) * 1999-06-22 2001-01-30 Cv Therapeutics, Inc. Propargyl phenyl ether A2A receptor agonists

Also Published As

Publication number Publication date
EP1414837B1 (de) 2005-10-19
NO327997B1 (no) 2009-11-09
ES2247371T3 (es) 2006-03-01
IL160231A0 (en) 2004-07-25
CA2456744A1 (en) 2003-02-20
KR20040023733A (ko) 2004-03-18
ZA200401000B (en) 2004-10-18
KR100923888B1 (ko) 2009-10-28
IL160231A (en) 2010-11-30
NZ530976A (en) 2005-07-29
DE60206775T2 (de) 2006-07-20
AU2002327426B2 (en) 2007-06-14
RU2004106635A (ru) 2005-07-27
NO20040969L (no) 2004-04-19
MXPA04001185A (es) 2005-06-17
DE60206775D1 (de) 2006-03-02
HUP0401437A3 (en) 2007-05-29
AU2002327426A2 (en) 2003-02-24
WO2003014137A1 (en) 2003-02-20
US20030078232A1 (en) 2003-04-24
CN1538972A (zh) 2004-10-20
DK1414837T3 (da) 2005-11-07
CN1244589C (zh) 2006-03-08
HUP0401437A2 (hu) 2004-11-29
RU2298557C2 (ru) 2007-05-10
EP1414837A1 (de) 2004-05-06
JP4357960B2 (ja) 2009-11-04
JP2005501842A (ja) 2005-01-20
PL368205A1 (en) 2005-03-21
AU2002327426C1 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
ATE307136T1 (de) Agonisten für den adenosin a3 rezeptor
CY1106424T1 (el) Παραγωγα ν-φαινυλ-πυρρολ γουανιδινης ως συνδετες υποδοχεις μελανοκορτινης
ATE305932T1 (de) Rapanycin29-enole
NO20041917L (no) Spesifikke midler som binder humant angiopoietin-2
EA200500520A1 (ru) Пуриновые соединения и их применение в качестве лигандов каннабиноидных рецепторов
EA200301215A1 (ru) Лиганды рецепторов 5-ht и их применение
AU2003205077A1 (en) Imaging agents and methods of imaging naaladase of psma
PT1444215E (pt) Derivados de 1,2,4-triadiazolio como moduladores do receptor de melanocortina
BR0208957A (pt) Ciclobuteno-1,2-dionas 3,4-dissubstituìdas como ligandos de receptor de quimiocina cxc
MXPA04000886A (es) Derivados de triazolil-imidazopiridina y triazolilpurinas empledos como ligandos del receptor de adenosina a2a y su uso como medicamentos.
DK1450811T3 (da) Forbindelser specifikke af adenosin A1- og A3-receptorer og anvendelser heraf
DK1622908T3 (da) Xanthin-derivater som A2B adenosin-receptor-antagonister
TR200102742T2 (tr) Rezorsinol türevleri
BR9913389B1 (pt) agentes de preparaÇço, bem como precesso para sua preparaÇço.
DE50301232D1 (de) Skibindung, insbesondere für den langlauf
MA27094A1 (fr) Derives triazolo-quinoline utiles en tant que ligands recepteurs d'adenosine.
WO2004022573A3 (en) Adenosine a3 receptor agonists
DE60206599D1 (de) Biotin-derivate und ihre konjugaten mit chelatierungsmitteln
ES2166045T3 (es) Procedimiento para la preparacion de compuestos de 4,6-bis(ariloxi)pirimidina asimetricos.
ATE333277T1 (de) Behandlung von dyskinesie
TR200001622T2 (tr) Asilatlı Hetero-Alisiklik Türevleri
RU2000116332A (ru) Антгельминтное средство
DE60203740D1 (de) Luminacine analoge und deren verwendung
ES1049315Y (es) Elementos de union para pinzas del pelo. .
ES1049482Y (es) Util para la fijacion del alma en instrumentos de cuerda.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1414837

Country of ref document: EP

REN Ceased due to non-payment of the annual fee